Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Abstract
Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no known cure, limited treatment options with minimal benefits, and significant unmet need for disease modifying therapies.
Aims: This study investigated memantine's impact on ALS progression, with an additional focus on the effects of memantine on cognitive and behavioral changes associated with the disease.
Methods: A randomized, double-blind, placebo-controlled clinical trial was conducted from December 2018 to September 2020. ALS patients were enrolled in-person and remotely across 13 sites in the United States. Participants were randomized to memantine (20 mg twice daily) or placebo in a 2:1 ratio and completed 36 weeks of treatment. The primary outcome of disease progression was assessed by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), and blood was collected for biomarker analysis.
Document Type
Article
Publication Date
1-2025
Digital Object Identifier (DOI)
https://doi.org/10.1002/mus.28287
Funding Information
This work was funded by FDA-OPD Grant no. R01FD003937.
Repository Citation
Bhai, Salman; Levine, Todd; Moore, Dan; Bowser, Robert; Heim, Andrew J.; Walsh, Maureen; Shibani, Aziz; Simmons, Zachary; Grogan, James; Goyal, Namita A.; Govindarajan, Raghav; Hussain, Yessar; Papsdorf, Tania; Schwasinger-Schmidt, Tiffany; Olney, Nick; Goslin, Kim; Pulley, Michael; Kasarskis, Edward J.; Weiss, Michael; Katz, Susan W.; Moser, Suzan; Jabari, Duaa; Jawdat, Omar; Statland, Jeffrey; Dimachkie, Mazen M.; Barohn, Richard; and Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group, "A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis" (2025). Neurology Faculty Publications. 97.
https://uknowledge.uky.edu/neurology_facpub/97
Included in
Medical Physiology Commons, Molecular and Cellular Neuroscience Commons, Neurology Commons, Physiology Commons
Notes/Citation Information
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2024 The Author(s). Muscle & Nerve published by Wiley Periodicals LLC.